| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725374 | Clinical Gastroenterology and Hepatology | 2017 | 56 Pages |
Abstract
In a randomized trial of 99 patients, we found that silymarin (700 mg, given 3 times daily for 48 weeks) did not reduce NAS scores by 30% or more in a significantly larger proportion of patients with NASH than placebo. Silymarin may reduce liver fibrosis but this remains to be confirmed in a larger trial. It appears to be safe and well tolerated. ClinicalTrials.gov: NCT02006498.
Keywords
FibroScanNAFLDFIB-4HbA1cGGTNASALTRandomized controlled trialASTAspartate aminotransferaseAlanine aminotransferasenonalcoholic steatohepatitisNonalcoholic fatty liver diseaseTreatmentSilybinFibrosis-4Low-density lipoproteinLDLNonalcoholic fatty liver disease activity scoreNash Glycated hemoglobinGamma glutamyl transpeptidase
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv Mahadeva,